上海医药上半年营收超1400亿元 应收账款规模有所扩张

经济参考网
Sep 01

近日,上海医药(601607.SH)披露2026年半年报。在医药流通行业整体仍处于调整期的背景下,公司扣非归母净利润实现两位数增长,主业盈利韧性凸显,公司应收账款规模随业务拓展有所扩张,资产质量与运营效率的平衡成为新课题。  半年报显示,上半年公司实现营业收入1474.70亿元,同比增长4.15%;归母净利润35.04亿元,同比下降21.40%,主要受去年同期并表和黄药业的收益推高基数影响;扣非...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10